Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood filter during heart bypass may prevent organ damage, but trial stopped early

NCT ID NCT06659289

Disease control Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called Efferon LPS that filters blood during heart surgery when a heart-lung machine is used. The goal was to see if it could prevent multiple organ failure, especially kidney damage. Only 14 people took part before the study was stopped, so the results are not reliable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Efferon LPS hemoperfusion device
What this could lead to
If it works, this device could reduce the risk of organ failure and kidney damage after heart surgery.
What could go wrong
The trial was terminated early with only 14 participants, so results are very limited. It is unclear if the device provides any real benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Nov 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Planned cardiac surgery (aortocoronary bypass, heart valve replacement, etc.) requiring the use of cardiopulmonary bypass Exclusion Criteria: * Emergency nature of cardiac surgery * Cases in which a surgical procedure is required in addition to an aortocoronary artery bypass graft operation * History of aortocoronary bypass surgery * History of hemato-oncology * Receiving immunosuppressive therapy for cancer and autoimmune diseases * Sepsis, acute heart failure, acute respiratory failure, acute kidney injury at the time of enrolment * Chronic kidney disease, stage 5D (requiring continuous hemodialysis) * Treatment with renal replacement therapy in the past 90 days * Presence of cirrhosis (\>5 Child-Pugh score) * Acute pulmonary embolism * Acute myocardial infarction within 3 weeks before elective surgery * Left ventricular ejection fraction (LVEF) less than 40% according to echocardiography * Acute cerebrovascular accident within 3 weeks before elective surgery * Pregnancy * Any other clinical condition of the patient that, in the opinion of the investigator, precludes inclusion in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart disorder acute kidney injury prevention target multiple organ dysfunction syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac disease Multiple organ dysfunction syndrome

Contacts and locations

Locations

  • Pavlov First Saint Petersburg State Medical University

    Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.